Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Journal of Medicinal Chemistry · 28.12.2023 · 66 (24) · 16464-16483
DOI: 10.1021/acs.jmedchem.3c00865 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 13.12.2023. Verfasst von Fang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237 Shandong P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Shandong Province, Key Technology Research and Development Program of Shandong Province.
Abstract (Originalsprache)
Cancer is a major threat to the lives and health of people around the world, and the development of effective antitumor drugs that exhibit fewer toxic effects is an important aspect of cancer treatment. PARP inhibitors are antitumor drugs that target pathways involved in DNA-damage repair. The currently approved PARP inhibitors include olaparib, niraparib, rucaparib, talazoparib, fuzuloparib, and pamiparib. Hematological toxicities associated with the simultaneous inhibition of PARP-1 and PARP-2 have limited the clinical applications of these drugs. The present review introduces the necessity for research on the development of selective PARP-1 inhibitors from the perspective of structural and functional mechanisms of PARP-1 inhibition. A review of recently reported selective PARP-1 inhibitors provides the foundation for exploring novel strategies for designing selective PARP-1 inhibitors from the perspective of structure-activity relationships combined with computer simulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237 Shandong P. R. China.
ORCID-Profile: Dayong Shi
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Shandong Province
- Key Technology Research and Development Program of Shandong Province
- Qingdao Science and Technology Benefit People Demonstration Guide Special Project
- Qingdao Emerging Industry Cultivation Project
Zitieren
APA
Liu, F., Chen, J., Li, X., Liu, R., Zhang, Y., Gao, C., & Shi, D. (2023). Advances in Development of Selective Antitumor Inhibitors That Target PARP-1. Journal of Medicinal Chemistry, 66(24), 16464-16483. https://doi.org/10.1021/acs.jmedchem.3c00865
Vancouver
Liu F, Chen J, Li X, Liu R, Zhang Y, Gao C, et al. Advances in Development of Selective Antitumor Inhibitors That Target PARP-1. Journal of Medicinal Chemistry. 2023;66(24):16464-16483. doi:10.1021/acs.jmedchem.3c00865
BibTeX
@article{Liu2023,
author = {Liu, Fang and Chen, Jiashu and Li, Xiangqian and Liu, Ruihua and Zhang, Yiting and Gao, Chenxia and Shi, Dayong},
title = {Advances in Development of Selective Antitumor Inhibitors That Target PARP-1},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {24},
pages = {16464--16483},
doi = {10.1021/acs.jmedchem.3c00865}
}
EUVIMED